ArticleDiscover oncology2026

Integration of a glutamine metabolism-based prognostic signature and a synergistic nanotherapeutic strategy targeting metabolic vulnerabilities in prostate cancer.

Wenya Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.